This segment focuses on the research and development of novel antiviral therapies for the treatment of fibromyalgia (FM). The primary focus is on IMC-1, a fixed-dose combination of famciclovir and celecoxib, designed to address the viral trigger believed to be associated with FM. Research and development activities include clinical trials to evaluate the efficacy and safety of IMC-1 in FM patients. The company utilizes a combination of pharmacological and clinical trial methodologies to assess the impact of IMC-1 on FM symptoms, including pain, fatigue, and other associated symptoms. The patient impact is significant, as FM is a chronic condition with limited effective treatments. IMC-1 aims to provide a new therapeutic option for patients. The company's market positioning is as a development-stage biotechnology company with a focus on unmet medical needs. Future opportunities include expanding the application of antiviral therapies to other conditions with viral triggers. Regulatory and clinical aspects involve obtaining FDA approval for IMC-1. The company is actively exploring partnerships and collaborations to advance its clinical programs.

This segment is dedicated to the research and development of treatments for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The company is investigating the potential of antiviral therapies to address the underlying causes of ME/CFS, focusing on the hypothesis that viral infections may play a role in the disease. Research and development activities include preclinical studies and clinical trials to evaluate the efficacy and safety of potential drug candidates. The company employs advanced methodologies in virology, immunology, and clinical trial design to understand the disease mechanisms and develop effective treatments. The therapeutic area is ME/CFS, a debilitating condition with significant unmet medical needs. The patient impact is aimed at improving the quality of life for ME/CFS patients by addressing the underlying causes of the disease. The company's market positioning is as a pioneer in developing antiviral therapies for ME/CFS. Future opportunities include expanding the pipeline of drug candidates and exploring partnerships to accelerate development. Regulatory and clinical aspects involve navigating the regulatory pathways for ME/CFS treatments. The company is actively seeking strategic partnerships and collaborations to advance its research and development efforts.